SCHOTT appoints Supervisory Board of SCHOTT Pharma AG & Co. KGaA

Friday, April 28, 2023, Mainz, Germany

  • New corporate body with shareholders’ representatives active until 2026
  • The Supervisory Board with Peter Goldschmidt as elected Chairman comprises long-standing know-how in the pharma industry and management expertise
SCHOTT AG has appointed new shareholder representatives to the Supervisory Board of SCHOTT Pharma, bringing a broad range of expertise and industry experience to its recently carved-out subsidiary. The new shareholders’ representatives of the Supervisory Board are Peter Goldschmidt (Chairman, 58), CEO of Stada AG; Dr. Wolfgang Wienand (Vice Chairman, 51), CEO of Siegfried Holding AG; Eva Kienle (55), CFO KWS Saat SE & Co. KGaA; and Ann-Kristin Erkens (47), Corporate Senior Vice President Financial and Business Controlling at Henkel Adhesive Technologies. The remaining Supervisory Board members include Christine Wening (43) and Mario Just (57) representing the employees of SCHOTT Pharma.
Supervisory Board of SCHOTT Pharma AG & Co. KGaA. Image: Three women and three men.
Supervisory Board of SCHOTT Pharma AG & Co. KGaA. Image: SCHOTT Pharma/Oana Szekely

With this move, SCHOTT is taking steps to ensure sustainable value creation for its SCHOTT Pharma business in line with international standards. SCHOTT Pharma AG & Co. KGaA is a pioneer in drug containment and delivery solutions for injectable drugs and has achieved a strong profitability, outperforming market growth rates in recent years according to its own estimates.

“SCHOTT Pharma is looking at exciting milestones ahead. The establishment of a Supervisory Board with members from outside the SCHOTT Group is a further important step towards SCHOTT Pharma’s capital market readiness. The newly appointed members have an excellent track record to govern the Management Team in taking full advantage of tremendous opportunities,” said Dr. Frank Heinricht, CEO of SCHOTT AG. The mandates are effective until the Annual General Meeting for the fiscal year ending 30 September 2026.

“Speaking on behalf of the Supervisory Board, we’re looking forward to contributing our expertise to SCHOTT Pharma’s exciting journey,” said Chairman Peter Goldschmidt. “SCHOTT Pharma has a strong track record and inspiring innovations in its pipeline, which hold the potential to further advance the pharma industry.”

About SCHOTT Pharma

SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world – because human health matters. The portfolio comprises drug containment and delivery solutions for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 65 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house, a state-of-the-art R&D center in Switzerland, and around 130 employees in R&D, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA, headquartered in Mainz, Germany, is part of SCHOTT AG that is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated sales of EUR 821 million in the fiscal year 2022.

Contact us

For more information about this media release, please contact me.

Get in touch
Christina Rettig, Head of Corporate Communications
Christina Rettig

Head of Corporate Communications